Integrum’s OPRA™ Implant System now available at Froedtert & the Medical College of Wisconsin
Orthopaedic services at Froedtert & Medical College Wisconsin now include the OPRA™ Implant System for above-knee amputations.
The Froedtert & the Medical College of Wisconsin health network is now using the OPRA™ Implant System, Integrum’s bone-anchored solution for the rehabilitation of amputees. The Froedtert & the Medical College of Wisconsin regional health network is a partnership between Froedtert Health and the Medical College of Wisconsin. The health network includes five hospitals, more than 1,700 physicians, and nearly 40 health centers and clinics, drawing patients from throughout the Midwest and the US.
The program at Froedtert & MCW is led by orthopaedic surgeon John C. Neilson, MD and physical medicine and rehabilitation specialist David R. Del Toro, MD.
Approximately 2 million people live with limb loss in the US, with up to three-quarters of patients undergoing a lower-extremity amputation experiencing problems with their socket prosthesis. Consequently, the consideration of osseointegration and bone-anchored prostheses as a viable option for specific amputees within the limb loss community continues to establish itself in the US market. This rapidly developing treatment for amputee care gained a considerable boost when the FDA awarded Integrum an HDE approval for the OPRA™ Implant System in July 2015. The subsequent years have seen the Department of Defense, University of California San Francisco, Johns Hopkins Hospital, Presbyterian St. Luke’s Medical Center Hospital, and Emory Healthcare adopt the technology.
“We are driven to improve the quality of lives of people with amputation by supporting leading health care providers deliver our innovative solutions,” says Maria Lopez, CEO of Integrum. “We are glad and excited to see Froedtert Hospital adopt our technology.”
To make an appointment at Froedtert & Medical College of Wisconsin, call +1 (414) 805-3666.
About the OPRA™ Implant System
Integrum’s OPRA™ Implant System is the only FDA-approved, bone-anchored prosthetic solution available in the United States. OPRA™ Implant System consists of an anchorage element (Fixture) and a skin penetrating device (Abutment). The Fixture is surgically inserted into the femur, and after a healing time of several months, the Abutment is connected to the Fixture. The prosthetic leg is then attached directly to the Abutment via the Axor™, a prosthetic connection and safety device.
This disclosure contains information that Integrum AB is obliged to make public pursuant to the EU Market Abuse Regulation (EU nr 596/2014). The information was submitted for publication, through the agency of the contact person, on 30-10-2020 10:00 CET. Integrum is listed on Nasdaq First North in Stockholm. Erik Penser is the Company's Certified Adviser.
For further information, please contact:
Maria Lopez, CEO
Cell. 0708-46 10 69
Email: maria.lopez@integrum.se
Certified Adviser:
Erik Penser Bank AB
Tel. +46 8 463 8000
Email: certifiedadviser@penser.se
Integrum AB is a publicly traded company (INTEG B: Nasdaq First North exchange) based outside of Gothenburg, Sweden with a U.S. subsidiary in San Francisco, CA. Since 1990 the OPRA™ Implant System has been helping individuals with amputations towards an improved quality of life. Thorough surgical experience gained over more than three decades from 500 surgeries in 14 countries has led to the development of Integrum’s system for bone-anchored prosthetics – a beneficial alternative to the traditionally used socket prosthesis. Integrum’s OPRA™ Implant System was approved by the U.S. Food and Drug Administration (FDA) in 2015 for use in the U.S. under a Humanitarian Use Device (HUD) designation which was reviewed through the Humanitarian Device Exemption (HDE) pathway. The OPRA™ Implant System is the only FDA approved technology for above-knee, bone-anchored prosthetics available in the U.S. More information on the company and its innovative solutions for amputees can be found at www.integrum.se.
